PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy. Electronic address: giulia.mallucci@mondino.it.\', \'Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.\', \'Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.\', \'Neuroimmunology research Unit/Neuroncology and Neuroinflammation Unit, IRCCS Mondino Foundation, Pavia, Italy.\', \'Neuroimmunology research Unit, IRCCS Mondino Foundation, Pavia, Italy.\', \'Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S2211-0348(21)00020-110.1016/j.msard.2021.102754
?:hasPublicationType
?:journal
  • Multiple sclerosis and related disorders
is ?:pmid of
?:pmid
?:pmid
  • 33609958
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.123
?:rankingScore_hIndex
  • 18
is ?:relation_isRelatedTo_publication of
?:title
  • Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all